Technology
Health
Biotechnology

Ascendis Pharma

$123.22
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$1.17 (-0.94%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell ASND and other stocks, options, ETFs, and crypto commission-free!

About

Ascendis Pharma A/S American Depositary Shares, also called Ascendis Pharma, is a biopharmaceutical company, which engages in the development of drug candidates. Through its TransCon technology, it develops a pipeline of sustained release prodrug therapies including endocrinology product candidates to support the market. Read More The company was founded by Jan Moller Mikkelsen and Harald Rau in September 2006 and is headquartered in Hellerup, Denmark.

Employees
121
Headquarters
Hellerup, Capital Region
Founded
2006
Market Cap
5.23B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
182.16K
High Today
$125.04
Low Today
$121.99
Open Price
$123.62
Volume
225.59K
52 Week High
$131.76
52 Week Low
$53.21

Collections

Technology
Health
Biotechnology
Biopharmaceutical
Pharmaceutical
Europe (Non-UK)
Europe

News

Yahoo FinanceMar 12

What Makes Ascendis Pharma A/S (ASND) a New Buy Stock

Ascendis Pharma A/S (ASND) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system. ...

429
Markets InsiderMar 12

Ascendis Pharma - It's Been All About Growth...

(RTTNews) - Shares of Ascendis Pharma A/S (ASND) closed yesterday's trading at an all-time high of $125.29, and that represents a gain of nearly 100% year-to-date.

197
Seeking AlphaMar 9

Ascendis Proves Technology Platform With Big Win In Major Indication

Recently, Ascendis Pharma (ASND) announced positive results from its phase 3 Growth Hormone Deficiency (GHD) study. Specifically, its TransCon human growth hormone (hGH) met the primary endpoint in children with growth hormone deficiency (GHD). The main goal was to see if TransCon hGH could prove to be non-inferior to standard daily injection treatment with Genotropin. This provides patients a new option and a more superior way to improve their lives. These results are substantial and this is only the begin...

305

Earnings

-$1.25
-$0.85
-$0.44
-$0.04
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
Actual
Expected Mar 27, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.